Covaxin Shows Interim Efficacy Of 81% In Phase 3 Results: Bharat Biotech

PUBLISHED ON: March 3, 2021 | Duration: 2 min, 42 sec

  
loading..
Phase 3 results for Bharat Biotech's coronavirus vaccine - Covaxin - were released Wednesday afternoon, with the drug demonstrating "81 per cent interim efficacy in preventing COVID-19 in those without prior infection after the second dose", according to a statement by the company.
ALSO WATCH
Data Suggests Covishield Efficacy Comes Down To 10-20% Against South African Strain: Randeep Guleria

................................ Advertisement ................................

................................ Advertisement ................................

Listen to the latest songs, only on JioSaavn.com